Question explored with the scientific record
Conversation so far
- 1 what is naltrexone for/do?
- 2 what about use in long covid?
Answered on this page ↓
what about use in long covid?
Low-dose naltrexone for long COVID is a plausible idea with thin evidence: one small unblinded study, no placebo, no hard outcomes.
The best data here is an open-label study of 38 long COVID patients on 1 to 3 mg daily for 2 to 3 months, reporting less pain, better mood, and less chest tightness and cough, all self-reported, with no placebo group [4]. That design cannot separate the drug from time, rest, or expectation. A 2025 review calls the rationale real (it may calm microglial inflammation) but says randomized evidence is limited and trials are still needed [2]. The same review lumps LDN with immunoadsorption and IVIG as small prospective studies showing improvement [3].
| Therapy | Design | Result |
|---|---|---|
| Low-dose naltrexone, 38 patients | Open-label, no placebo | Symptom reduction, p<0.05 [4] |
| IVIG vs albumin, POTS | Double-blind RCT | 46.7% vs 38.5% response, not significant [1] |
| Efgartigimod, post-COVID POTS | Phase 2 RCT, 53 patients | No meaningful improvement [2] |
Note the pattern: when these immune-targeting drugs got a real placebo-controlled trial, the signal vanished [1][2]. LDN has not had that test in long COVID. The animal naltrexone records in this set are about tumors, hormones, and fear learning, not long COVID, so they tell you nothing here.
My call: reasonable to try at low dose given its safety profile, but do not expect proof of benefit, because none exists yet. Confidence: low.
Sources used 4
-
Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction
Narrative review finds case reports and small studies suggest immunotherapies may benefit some POTS, autonomic disorder, and Long COVID patients, but controlled trials show no clear benefit and larger trials are needed.
DOI: 10.3389/fcimb.2025.1647203 -
Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review
A scoping review synthesizing nine potential pharmacologic options for post-acute sequelae of COVID-19 (PASC), summarizing mechanisms, evidence, and gaps, and concluding that heterogeneity of symptoms necessitates standardized, targeted trials.
DOI: 10.1186/s12879-025-11131-x -
Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: A role for endogenous opioid systems in cancer
The study shows that in mice bearing neuroblastoma, the duration of opiate receptor blockade by naltrexone, not the daily dose, determines tumorigenic outcomes and survival, implicating the endogenous opioid system in cancer regulation with schedule-dependent pro- or anti-tumor …
DOI: 10.1016/0024-3205(84)90651-9 -
Effect of Naltrexone on photoperiodic regulation of testicular steroidogenesis in adult golden hamster, Mesocricetus auratus
This study investigates the role of Naltrexone, an l-opioid receptor antagonist, in the photoperiodic regulation of testicular steroidogenesis in adult golden hamsters, revealing that Naltrexone administration enhances steroidogenic marker expression and testosterone levels unde…
DOI: 10.1016/j.ygcen.2015.10.001